Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More
Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More
May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More
May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More
